Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

 Full screen view
Filter results: >>>>
Cell Small Molecule Small Mol Concentration (uM) Primary Target Pathway Mean Normalized Growth Rate Inhibition Value Increased Fraction Dead
HCC1806 Ipatasertib
0.1
AKT
PI3K/mTOR
 1.0178 -0.00290
HCC1806 Ipatasertib
0.31623
AKT
PI3K/mTOR
 0.9726 -0.00130
HCC1806 Ipatasertib
1.0
AKT
PI3K/mTOR
 1.0055 -0.00454
HCC1806 Ipatasertib
3.1623
AKT
PI3K/mTOR
 0.9502 -0.00032
HCC1806 Ipatasertib
10.0
AKT
PI3K/mTOR
 0.9450 -0.00218
HCC1806 Alpelisib
0.001
PI3Ka
PI3K/mTOR
 0.9949 -0.00435
HCC1806 Alpelisib
0.0031623
PI3Ka
PI3K/mTOR
 1.0240 0.00564
HCC1806 Alpelisib
0.01
PI3Ka
PI3K/mTOR
 0.9729 0.00377
HCC1806 Alpelisib
0.031623
PI3Ka
PI3K/mTOR
 1.0199 0.00068
HCC1806 Alpelisib
0.1
PI3Ka
PI3K/mTOR
 0.9909 0.00150
HCC1806 Alpelisib
0.31623
PI3Ka
PI3K/mTOR
 0.9494 0.00073
HCC1806 Alpelisib
1.0
PI3Ka
PI3K/mTOR
 0.9884 0.00158
HCC1806 Alpelisib
3.1623
PI3Ka
PI3K/mTOR
 0.8853 0.01047
HCC1806 Alpelisib
10.0
PI3Ka
PI3K/mTOR
 0.7260 0.01759
HCC1806 Taselisib
0.001
PI3Ka, g, d
PI3K/mTOR
 1.0144 -0.00169
HCC1806 Taselisib
0.0031623
PI3Ka, g, d
PI3K/mTOR
 1.0056 0.00257
HCC1806 Taselisib
0.01
PI3Ka, g, d
PI3K/mTOR
 0.9779 -0.00163
HCC1806 Taselisib
0.031623
PI3Ka, g, d
PI3K/mTOR
 0.8712 0.02222
HCC1806 Taselisib
0.1
PI3Ka, g, d
PI3K/mTOR
 0.7930 0.02340
HCC1806 Taselisib
0.31623
PI3Ka, g, d
PI3K/mTOR
 0.7953 0.03517
HCC1806 Taselisib
1.0
PI3Ka, g, d
PI3K/mTOR
 0.5970 0.05851
HCC1806 Taselisib
3.1623
PI3Ka, g, d
PI3K/mTOR
 0.4011 0.10718
HCC1806 Taselisib
10.0
PI3Ka, g, d
PI3K/mTOR
 -0.0297 0.29879
HCC1806 TGX221
0.001
PI3Kb
PI3K/mTOR
 1.0544 0.00368
HCC1806 TGX221
0.0031623
PI3Kb
PI3K/mTOR
 1.0251 0.00072